Hepion Pharmaceuticals (Hepion Pharmaceuticals) FCF Margin % : 0.00% (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Hepion Pharmaceuticals FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Hepion Pharmaceuticals's Free Cash Flow for the three months ended in Dec. 2023 was $-9.00 Mil. Hepion Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Therefore, Hepion Pharmaceuticals's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

As of today, Hepion Pharmaceuticals's current FCF Yield % is -547.45%.

The historical rank and industry rank for Hepion Pharmaceuticals's FCF Margin % or its related term are showing as below:

HEPA's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -148.935
* Ranked among companies with meaningful FCF Margin % only.

Hepion Pharmaceuticals FCF Margin % Historical Data

The historical data trend for Hepion Pharmaceuticals's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hepion Pharmaceuticals FCF Margin % Chart

Hepion Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

Hepion Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Hepion Pharmaceuticals's FCF Margin %

For the Biotechnology subindustry, Hepion Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hepion Pharmaceuticals's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hepion Pharmaceuticals's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Hepion Pharmaceuticals's FCF Margin % falls into.

Hepion Pharmaceuticals FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Hepion Pharmaceuticals's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-40.903	/	0
	=	%

Hepion Pharmaceuticals's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-9.002	/	0
	=	%

Hepion Pharmaceuticals FCF Margin % Related Terms

Thank you for viewing the detailed overview of Hepion Pharmaceuticals's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Hepion Pharmaceuticals (Hepion Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hepion Pharmaceuticals Inc (NAS:HEPA) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

399 Thornall Street, First Floor, Edison, NJ, USA, 08837

Website

https://www.hepionpharma.com

Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.

Executives

Peter Wijngaard	director	8 SYLVAN WAY, PARSIPPANY NJ 07054
Robert T Foster	officer: Chief Scientific Officer	C/O CONTRAVIR PHARMACEUTICALS, INC., 399 THORNALL STREET, FIRST FLOOR, EDISON NJ 08837
Kaouthar Lbiati	director	399 THORNALL STREET, FIRST FLOOR, EDISON NJ 08837
Anand Reddi	director	399 THORNALL STREET, FIRST FLOOR, EDISON NJ 08837
John T Cavan	officer: Chief Financial Officer	C/O STEMLINE THERAPEUTICS, INC., 750 LEXINGTON AVENUE, 6TH FLOOR, NEW YORK NY 10022
John P Brancaccio	director	C/O TAMIR BIOTECHNOLOGY, INC., 11 DEER PARK DRIVE, SUITE 204, MONMOUTH JUNCTION NJ 08852
Gary S Jacob	director, officer: CEO and President
Donald E Garlikov	10 percent owner	41 S. HIGH STREET, SUITE 3400, COLUMBUS OH 43215
Tamar D Howson	director
Thomas Phd Adams	director
Gabriel Cerrone	10 percent owner	VIA SANT' ANDREA 18, MILAN L6 20121
John Z Sullivan-bolyai	officer: Chief Medical Officer	C/O CONTRAVIR PHARMACEUTICALS, INC., 399 THORNALL STREET, 1ST FLOOR, EDISON NJ 08837
James Sapirstein	director, officer: Chief Executive Officer	1517 SAN JACINTO, HOUSTON TX 77002
Arnold Lippa	director	C/O AURORA CAPITAL, LLC, 17 PARK AVENUE, #201, NEW YORK NY 10016
William Karl Hornung	officer: Chief Financial Officer	C/O CONTRAVIR PHARMACEUTICALS, INC., 420 LEXINGTON AVE., SUITE 300, NEW YORK NY 10170